<DOC>
	<DOCNO>NCT01525914</DOCNO>
	<brief_summary>Hypothesis : That , men surveillance favorable risk prostate cancer treat dutasteride , prostate specific antigen ( PSA ) kinetics value identify men harbor occult high grade prostate cancer . The study determine prevalence secondary rise PSA &gt; 0.5 ng/ml PSA double time subject surveillance treat dutasteride .</brief_summary>
	<brief_title>Response Patients Surveillance Prostate Cancer Dutasteride</brief_title>
	<detailed_description>This analysis subset data associate active surveillance cohort Sunnybrook Health Sciences Centre . Approximately 150 subject within cohort receive dutasteride therapy 6 month 3 year . All subject serial PSAs regular interval 3 6 month , biopsy perform within 1 3 year initiate dutasteride . The prevalence secondary rise PSA &gt; 0.5ng/ml calculate impact dutasteride therapy PSA doubling time . This information correlate baseline PSA value , prostate volume , extent disease initial biopsy baseline PSA kinetics . PSA kinetics also correlate Gleason score upgrade repeat biopsy . The rate negative biopsy men dutasteride therapy compare similar group surveillance subject treat dutasteride .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Patients active surveillance favorable risk prostate cancer treat dutasteride follow diagnosis cancer .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>PSA kinetics</keyword>
	<keyword>PSA doubling time</keyword>
	<keyword>active surveillance</keyword>
</DOC>